CVRX · CVRx, Inc.
$5.94
+0.36 (+6.45%)
At close · Aug 6
Earnings today
Market Cap
$157.62M
Shares
26.54M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.58
Open$5.49
Day$5.29–5.64
52W$4.37–11.30
Avg vol 30d258K
Short int1.9M · 7.3% float · 8.9d
Short vol46%
Last earningsAug 6, 2026
DataJun 2021–Aug 2026
Filing10-Q · Aug 6
Up next
Earnings call today
Aug 6, 2026
Today
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−23%
below
Price vs 50-day avg
+6%
above
RSI (14)
57
neutral
MACD trend
Positive
52-week position
17%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+6%
trailing
6-month return
−8%
trailing
YTD return
−21%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
23 of 99 funds reported for Jun 30 · net +78.2K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.26% of float · ▲ +4.7% MoM · 8.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
99 holders — near 3-yr high, broad support
Squeeze score
86
high risk · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
Gross margin
85%
expanding
EPS growth
+23%
Y/Y
Free cash flow
$-40.8M
Balance sheet
$26.2M
net cash
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
full year of 2026
Total revenue
Lowered
$58M – $60M
prior FY $56.65M
midpoint +4.1% Y/Y
Gross margin
Raised
86% – 87%
Operating expenses
Lowered
$99M – $101M
third quarter of 2026
Total revenue
Initiated
$13.5M – $14.5M
prior qtr $14.77M
midpoint −5.2% QoQ
Guided vs delivered
· last 3 settled
Total revenue
full year of 2025
guided $63M – $65M
$56.65M
Miss −11.5%
Total revenue
first quarter of 2025
guided $14.5M – $15M
$12.35M
Miss −16.3%
Total revenue
full year of 2024
guided $50.5M – $51.5M
$51.29M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−23%
Bearish
Price vs 50-day avg
+6%
Bullish
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
17%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
23 of 99 funds reported for Jun 30 · net +78.2K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.26% of float · ▲ +4.7% MoM · 8.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
99 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $6 · 17%
52-wk high $11
vs 200-day avg -23%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Active implanting centers in the U.S. | 258 | second quarter of 2026 | — |
|
|
|||
| Revenue units in the U.S. | 466 | the three months ended June 30, 2026 | — |
|
|
|||
| Sales territories in the U.S. | 56 | as of June 30, 2026 | +5.7% |
|
|
|||
| Total revenue units in Europe | 40 | the three months ended June 30, 2026 | — |
|
|
|||
| 30-day approval rate for Medicare Advantage prior authorizations | 50% | first two months of 2026 | — |
| Active implanting centers | 252 | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CVRX
this stock
CVRx, Inc.
|
$157.62M | -21.4% | +30.5% | — | 7.3% |
|
ABT
Abbott Laboratories
|
$186.86B | -14.1% | +5.7% | 30.1 | 1.4% |
|
SYK
Stryker Corp
|
$129.28B | -3.6% | +11.2% | 34.9 | 1.8% |
|
MDT
Medtronic plc
|
$110.07B | -8.9% | +8.4% | 23.1 | 1.5% |
|
BSX
Boston Scientific Corp
|
$71.45B | -49.9% | +5.5% | 20.0 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CVRX | +12.7% | +5.9% | -8.2% | +7.8% | -21.4% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | +7.2% | +2.6% | -19.5% | +4.8% | -34.3% |
Key facts
CIK
1235912
CUSIP
126638105
13F (30d)
18 filings
18 filers
Visit website
Investor relations